Source comparison
CJC-1295 Concentration Comparison
0.25mg/mL 800μL (requires multi-site injection) Moderate. Higher dilution accelerates degradation Low Not recommended. Impractical volume 0.5mg/mL 400μL (high volume, larger syringe required) Moderate. Degradation ~6–8% over 28 days Acceptable for low-dose pro
This comparison does not assign a generated winner or score.
- 0.25mg/mL
- 800μL (requires multi-site injection)
- Moderate. Higher dilution accelerates degradation
- Low
- Not recommended. Impractical volume
- 0.5mg/mL
- 400μL (high volume, larger syringe required)
- Moderate. Degradation ~6–8% over 28 days
- Acceptable for low-dose protocols only
- 1mg/mL
- 200μL (standard insulin syringe compatible)
- High. Degradation ~3–5% over 28 days
- Research standard. Optimal balance
- 2mg/mL
- 100μL (low volume, high precision required)
- Moderate. Aggregation possible in some batches
- Acceptable for experienced researchers
- 3mg/mL+
- 67μL or less (micro-dosing required)
- Moderate. Aggregation risk increases sharply
- High. Visible turbidity after 7–10 days
- Not recommended. Stability compromised